European Medicines Agency Accepts Marketing Authorization Application For Biovest International, Inc.’s Cancer Vaccine For Treatment Of Non-Hodgkin’s Follicular Lymphoma
1/13/2014 10:57:09 AM
MINNEAPOLIS & TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (“Biovest”), a leader and pioneer in the development of personalized cancer immunotherapies, today reported that the European Medicines Agency (EMA) accepted the Company’s Marketing Authorization Application (MAA) for BiovaxID™ (submitted to EMA as “Dasiprotimut-T Biovest”), a personalized cancer vaccine for the treatment of non-Hodgkin’s follicular lymphoma. The MAA validation confirms the submission is complete and begins the formal EMA review process intended to secure approval to market BiovaxID in the European Union and to allow prescription and sale of BiovaxID for the treatment of non-Hodgkin’s follicular lymphoma in patients who have achieved a first complete remission.
Help employers find you! Check out all the jobs and post your resume.
comments powered by